Home » Newsletters » BioWorld Science

BioWorld Science

June 5, 2001

View Archived Issues

Highlights from NeuroSearch 2000 Annual Report

NO-related cardioprotective effects of NCX-4016 confirmed in rats

Atrasentan delays disease progression in HRPCa

Agreement signed for U.S. promotion of AndroGel

AUA news: AII antagonist, ACE inhibitor protect against postischemic acute renal failure

Zelmac regulatory application voluntarily withdrawn in E.U.

STI-571 + paclitaxel as promising therapeutic strategy for prostate cancer with bone metastasis

Aventis receives approvable letter from FDA for first-in-class antibiotic

Enzyme mimetic advances to clinical trials following FDA IND approval

Thiazolidinediones potentially useful in renal cell carcinoma therapy, according to AUA presentation

Palatin's PT-141 ED treatment well tolerated in phase I trial

European authorities grant orphan drug designation for pemtumomab

FR-901228 enhances suicide cancer gene therapy by increasing transgene expression

Topical immune response modifier provides high response rate in phase II trial in sBCC

Tularik forms new company to focus on antibacterial and antifungal drugs

Oral suspension of Trileptal for epilepsy approved by FDA

Ad-RB94 gene therapy shows potential in pancreatic and squamous cell H&N cancer

Herceptin reaches market in Japan

LMW dendritic polymers and their uses reported in recent patent

Fab I inhibitors useful as antibacterial and antifungal agents

PPAR agonists from Kyorin claimed for use in metabolic diseases

BMS studies new Na+/H+ exchange inhibitors with antianginal, cardioprotective properties

Somatostatin receptor modulators in development at Takeda

Patent covers Ferring's new vasopressin V2 receptor agonists and uses

nAChR ligands particularly useful for the Rx of cognition disorders

Prous Science inaugurates Advanced Internet TTMed Channel in Anaheim

Company Profile: YM BioSciences

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...